Comparison of PBC patients who have adequate response to UDCA in combination with fibrates therapy but not to UDCA monotherapy may obtain novel biomarkers which could predict disease progression and treatment response, such as sCD163. The gene discussed is CD163; the disease is primary biliary cholangitis.